key: cord-0951006-cxcr0a1c
authors: Wei, W.; Ortwine, J. K.; Mang, N. S.; Joseph, C.; Hall, B. C.; Prokesch, B. C.
title: Limited Role for Antibiotics in COVID-19: Scarce Evidence of Bacterial Coinfection
date: 2020-06-18
journal: nan
DOI: 10.1101/2020.06.16.20133181
sha: 608d98badfb57be00815b7f7692b3f4aa65553ab
doc_id: 951006
cord_uid: cxcr0a1c

Background: There is currently a paucity of data describing bacterial coinfections, related antibiotic prescribing patterns, and the potential role of antimicrobial stewardship in the care of patients infected with SARS-CoV-2. Methods: This prospective, observational study was conducted from March 10, 2020 to April 21, 2020 in admitted patients with confirmed COVID-19. Patients were included if [≥] 18 years old and admitted to the hospital for further treatment. Data was collected via chart review from the enterprise electronic health record database. Data collected include factors driving antibiotic choice, indication, and duration of therapy as well as microbiological data. Findings: Antibiotics were initiated on admission in 87/147 (59%) patients. Of these, 85/87 (98%) prescriptions were empiric. The most common indication for empiric antibiotics was concern for community-acquired pneumonia (76/85, 89%) with the most prescribed antibiotics being ceftriaxone and azithromycin. The median duration of antibiotic therapy was two days (interquartile range 1-5). No patients had a community-acquired bacterial respiratory coinfection, but 10/147 (7%) of patients were found to have concurrent bacterial infections from a non-respiratory source, and one patient was diagnosed with active pulmonary tuberculosis at the time of admission for COVID-19. Interpretation: Bacterial coinfection in patients with COVID-19 was infrequent. Antibiotics are likely unnecessary in patients with mild symptoms. There is little role for broad-spectrum antibiotics to empirically treat multidrug resistant organisms in patients with COVID-19, regardless of disease severity. Antimicrobial stewardship remains important in patients infected with SARS-CoV-2.

3 Introduction:

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China and found to cause acute respiratory symptoms and pneumonia. The disease caused by SARS-CoV-2 was named coronavirus disease 2019 (COVID-19). SARS-CoV-2 has led to a global pandemic affecting over 200 countries. 1 In the United States, cases continue to increase with over one million confirmed infections and 73,000 associated deaths as of May 2020. 2 Patients with COVID-19 present with a variety of signs and symptoms but the majority exhibit fever, dry cough, and fatigue. Many patients also experience shortness of breath, myalgias, and anorexia amongst other less common symptoms. Disease severity can range from asymptomatic or relatively mild to severe with an estimated 20% of patients requiring admission to an intensive care unit (ICU). 3 Chest imaging of patients with COVID-19 typically reveals bilateral multi-focal opacities on plain radiographs and bilateral, peripheral interstitial ground glass opacities on computerized tomography (CT). 2, 3 These findings are nonspecific and overlap with other infectious etiologies, creating uncertainty in differentiating COVID-19 from other common viral or bacterial respiratory infections. Thus, if bacterial pneumonia or sepsis is strongly suspected, initiation of empiric antibiotics to cover for communityacquired pneumonia (CAP) has been recommended by national guidelines. 3, 4 Bacterial infections occur both concomitantly and subsequent to a variety of viral respiratory illnesses. In the preantibiotic era of the 1918 influenza pandemic, bacterial infections complicated nearly all influenza-related deaths.

More recently during the 2009 influenza A (H1N1) pandemic, bacterial infections were identified in up to 34% of ICU managed patients. 5 In a typical, non-pandemic influenza season, nearly 20% of patients are diagnosed with community-acquired bacterial infections, most commonly caused by Staphylococcus aureus and Streptococcus pneumoniae. 5, 6 However, there is currently a paucity of data describing bacterial infections and related antibiotic prescribing in patients with COVID-19.

The continued development of antimicrobial resistance globally may be exacerbated in the setting of an infectious pandemic. Thus, in light of the rising number of COVID-19 cases worldwide, we believe that it is of utmost importance to continue promoting the judicious use of anti-infective agents and highlight the role of antimicrobial stewardship. The goal of this study is to assess how often patients with SARS-CoV-2 infection have clear evidence of concurrent bacterial infections and to better characterize the factors driving antibiotic prescribing, selection, and duration of therapy in this cohort of patients. This information is critical to defining the role of antimicrobial . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint stewardship in assisting with antibiotic de-escalation and discontinuation in the management of patients with COVID-19.

This prospective, observational study was conducted at Parkland Health & Hospital System and included patients admitted between March 10, 2020 and April 21, 2020. Parkland is an 862-bed safety net hospital as well as the primary teaching site for the University of Texas Southwestern (UTSW) Medical School providing care to underserved residents of Dallas County in Dallas, Texas and averages over one million patient visits annually. The study was approved by the UTSW Medical Center institutional review board and informed consent was waived.

Patients were included if they tested positive for SARS-CoV-2 by polymerase chain reaction (PCR), were 18 years of age or older, and were admitted to the hospital for management of COVID-19. Patients were excluded if the index admission for COVID-19 was at an outside facility.

Patient charts were retrospectively reviewed and data was collected from the enterprise electronic health record database by the primary investigator and study personnel. Baseline characteristics collected include demographic information, significant comorbidities, smoking history, history of intravenous (IV) antibiotic exposure in the 90 days prior to admission, and COVID-19 disease severity. In addition, data regarding fever, white blood cell (WBC) count, oxygen requirement, pulmonary imaging findings, pathogen-directed infectious work up, requirement of mechanical ventilation, vasopressors, continuous renal replacement therapy, length of stay, infection with Clostridioides difficile during admission, and in-hospital mortality related to COVID-19 were collected. Antibiotics initiated within 48 hours of admission were recorded along with rationale, therapeutic indication, and duration of use. Antibiotics that were initiated greater than 48 hours after time of admission were considered treatment for a possible secondary bacterial infection, rather than coinfection upon admission, and thus were excluded. Clinical data and outcomes were monitored through June 1 st ,, 2020.

From March 10, 2020 to March 27, 2020, patients were confirmed to have SARS-CoV-2 via PCR testing on nasopharyngeal and oropharyngeal samples through outside testing facilities. On March 27, 2020, Parkland . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 18, 2020. 

Patients who received antibiotics on admission were compared to those who did not in order to characterize the factors driving antimicrobial prescribing in patients presenting with COVID-19. In addition, patients were assessed for evidence of community-acquired bacterial respiratory coinfection (CABRC) as well as concurrent bacterial infections from a non-respiratory source on admission.

The severity of COVID-19 was defined using an institution-specific management algorithm (See Supplementary Material). Fever was defined as greater than 100·4 °F (38 °C). Leukopenia and leukocytosis were defined as a WBC count less than 4,000 cells/μL or greater than 11,000 cells/μL, respectively. CABRC was defined as presence of a positive bacterial culture consistent with CAP within 48 hours of admission and clinical signs and symptoms consistent with CAP as documented by the treatment team. Concurrent bacterial infection was defined as a positive non-respiratory bacterial culture within 48 hours of admission plus documentation consistent with active infection.

Continuous measurements were presented as means and standard deviations (SD) or medians and interquartile ranges (IQR) and evaluated using Student's t-test, or Mann-Whitney U test, respectively. Categorical variables were presented as counts (%) and evaluated using a χ2 test or Fisher's exact test.

This study had no funder. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

A total of 151 patients met inclusion criteria with 147 ultimately included in the study. Four patients were excluded due to having their index admission for COVID-19 at an outside facility. The average age of patients was 52 years and 60/147 (41%) were female (Table 1 ). One or more comorbidities were found in 114/147 patients (78%), with 16 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint patients (11%) having underlying chronic lung disease and 21 patients (14%) reporting being active cigarette smokers. Patients were admitted to the hospital after experiencing a median of 5 days (interquartile range, 3 to 7) of symptoms with the majority presenting with moderate severity COVID-19 disease (109/147, 74%). Seventeen patients (12%) met the criteria for severe COVID-19 with 10 (7%) requiring either mechanical ventilation or vasopressor support on admission.

Antibiotics were initiated within 48 hours of admission in 87/147 patients (59%). Of these, 85 patients (98%) received antibiotics as empiric therapy, and 2 (2%) had antibiotics continued from an outpatient course. The most common indication for empiric antibiotics ( Table 2 ) was CAP (76/85, 89%). The median duration of antibiotic therapy for any indication was 2 days (interquartile range, 1 to 5). Following the introduction of in-house PCR testing for SARS-CoV-2, a shorter duration of antibiotic therapy was noted ( Figure 1 ). The majority of patients (74/85, 87%) were exposed to two or more antibiotics during the empiric course of therapy, most commonly ceftriaxone and azithromycin (Table 3) . Broad-spectrum antibiotic therapy (vancomycin, piperacillin/tazobactam, and/or cefepime) was prescribed in only 24/147 (16%) patients. Of these 24 patients, only four patients had a recent history of IV antibiotic exposure in the 90 days prior to admission and none had a history of MRSA or Pseudomonas aeruginosa.

Antibiotic prescribing was significantly more common in patients with severe disease, evidence of pneumonia on imaging, leukocytosis, or supplemental oxygen requirements on admission. Patients who presented with mild disease were significantly less likely to receive antibiotics. There was no difference in frequency of antibiotic prescribing in patients with moderate disease or in those who were febrile on admission. Patients initiated on antibiotics upon admission also underwent a significantly more robust infectious workup than those who were not started on empiric antibiotic therapy ( CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint were identified in our patient cohort. However, clinical suspicion remained high enough that 19/76 (25%) patients who received empiric antibiotics for CAP on admission completed at least five days of therapy. Overall, 10/147 (7%) of patients were found to have concurrent bacterial infections unrelated to a respiratory source and one patient was diagnosed with active pulmonary tuberculosis (Table 4 ). Although nine patients were found to have positive blood cultures on admission, eight cultures were deemed contaminants (see Supplementary Material). One patient was considered to have a veritable bacteremia which was secondary to a gastrointestinal source. Similarly, ten patients had positive urine cultures on admission, but only five were considered pathogenic per treatment team documentation.

Early epidemiological studies of patients with COVID-19 reported empiric antibiotic use in 71-100% of patients, with Chen and colleagues reporting a median duration of therapy of five days (interquartile range, 3 to 7). 7-11

Comparatively, we found lower rates of empiric antibiotic utilization with shorter durations of therapy overall.

Longer durations of therapy were noted earlier in the outbreak and may be correlated with lengthy turnaround times (more than one week) to receive final SARS-CoV-2 testing results from a commercial reference laboratory. Once inhouse testing was established, turnaround times decreased dramatically with results typically available to clinicians within two hours. This likely contributed to increased levels of physician comfort in withholding empiric antibiotics in more stable patients given the prompt return of diagnostic testing, as well as facilitating more rapid antibiotic deescalation in those patients testing positive for COVID-19. The availability of rapid on-site testing for SARS-CoV-2 plays an important role in the decision-making process for discontinuation of antibiotic therapy. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint 8 combination therapy with an IV beta-lactam (e.g. ceftriaxone) plus azithromycin for patients admitted with CAP in the absence of risk factors for infections caused by multi-drug resistant organisms. 13 We observed limited use of broad-spectrum agents in general, though that may be because this study focused only on antibiotics prescribed within 48 hours of hospital admission. The ATS/IDSA CAP guidelines recommend empirically treating MRSA or Pseudomonas aeruginosa only if specific risk factors are present. These risk factors include recent hospitalization with receipt of IV antibiotics, prior history of either pathogen in the last 12 months, or high local prevalence rates for either pathogen. 13 Only four patients in this study had risk factors for multi-drug resistant (MDR) organisms, and therefore the majority of patients were appropriately prescribed narrow-spectrum antibiotics. Most of the patients initiated on broad-spectrum regimens were de-escalated quickly if MRSA surveillance screen and/or blood cultures were negative. Based on these observations, we recommend that careful assessment of MDR risk factors be performed before initiating broad-spectrum antibiotics and cultures should be obtained to help guide de-escalation. MRSA nasal screening has a negative predictive value of > 95% for MRSA pneumonia. The utilization of MRSA surveillance screening to assist with early de-escalation should be encouraged in order to decrease unnecessary exposure to vancomycin, lab draws and monitoring, and reduce risk of nephrotoxicity. 14, 15 There is currently limited information available regarding rates of bacterial coinfections with COVID-19. However, bacterial coinfection rates of 0-47% and 2-65% were reported in systematic reviews of pandemic influenza H1N1 and of influenza and other respiratory viruses, respectively. 16 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint coinfections among patients with respiratory viral illnesses, including COVID-19, are similar to the findings in our cohort of 147 patients. Interestingly, the average time to development of a bacterial superinfection in patients with influenza has been reported to be 7-14 days after the onset of the viral infection. 20 Therefore, the fact that none of the patients in our cohort were found to have definitive evidence of bacterial coinfection on admission is not unusual, as the patients presented a median of five days from symptom onset.

The median duration of antibiotic therapy in our cohort was short, indicating that suspicion for bacterial coinfection was low with only 19/147 (13%) patients receiving five days or more of empiric antibiotic therapy for CAP. Due to concern for increased infection transmission, most respiratory samples were collected from throat swabs rather than sputum or lower respiratory tract samples and half of the samples obtained from sputum were rejected due to being unsatisfactory quality specimens. Although identification of organisms may have been limited by this inability to obtain quality respiratory cultures, sputum cultures overall have poor yield for pathogen isolation. Our institution does not perform S. pneumoniae urine antigen testing; however, both S. pneumoniae and Legionella urine antigen tests have modest sensitivity for clinical disease and the most recent ATS/IDSA CAP guidelines do not recommend routinely testing these urine antigens in adults with non-severe CAP. 14 Procalcitonin has been suggested as a potentially useful biomarker to differentiate bacterial and viral infections and assist with antibiotic decisionmaking. 21-23 However, due to the lack of data regarding its reliability in completely ruling out bacterial pneumonia with accuracy, the role of procalcitonin in COVID-19 is currently unknown. 13, 24 Although blood cultures are not routinely recommended in non-severe CAP, they were collected from a majority of patients in this cohort. Blood culture results were ultimately not helpful in identifying clinically significant pathogens as nearly all organismal growth was considered to be from skin contamination. Therefore, blood cultures are likely not necessary in patients presenting with mild to moderate COVID-19 who do not meet the criteria for severe CAP.

In summary, we identified zero cases of CABRC in patients with COVID-19. While it is reasonable to initiate empiric antibiotics for possible bacterial infection in clinically severe patients awaiting diagnostic confirmation of COVID-19, broad-spectrum agents are likely unnecessary in the absence of risk factors for MDR organisms. Based on this study, it appears antibiotics are of limited utility in the setting of proven COVID pneumonia. If antibiotics are initiated, they should be de-escalated early in patients positive for SARS-CoV-2 with no other evidence of bacterial infection within 48 hours. Antimicrobial stewardship has an important role in limiting unnecessary antibiotic exposure and optimizing resources during this COVID pandemic.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. Figure   . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 18, 2020. Community-acquired bacterial respiratory infection 0 (0) 0 (0) 0 (0) ·· Concurrent bacterial infection from non-respiratory source 10 (7) 10 (11) 0 (0) 0·0056 Tuberculosis 1 (1) 1 (1) 0 (0) 1·00

Mechanical ventilation at anytime -n/total n(%) ┼ 29/141 (21) 23/81 (28) 6/60 (10) 0·0138

CRRT at anytime-n/total n(%) ┼ 5/141 (4) 4/81 (5) 1/60 (2) 0·394 Vasopressor support at anytime-n/total n(%) ┼ 22/141 (16) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint 

COVID-19) pandemic

World Health Organization

Center for Disease Control and Prevention

Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. National Institutes of Health

Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Bacterial coinfection in influenza: a grand rounds review

Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China

Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China

Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the

Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia

Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09

Amoxicillin/clavulanate 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 18, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 18, 2020. . https://doi.org/10.1101/2020.06.16.20133181 doi: medRxiv preprint